
## David Michonneau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9361394/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2019, 37, 375-385.	0.8	163
2	Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nature Genetics, 2018, 50, 1650-1657.	9.4	151
3	CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood, 2015, 125, 1830-1839.	0.6	144
4	In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity. Nature Medicine, 2016, 22, 64-71.	15.2	130
5	Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nature Communications, 2019, 10, 5695.	5.8	91
6	The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. Immunity, 2016, 44, 143-154.	6.6	76
7	Allogeneic reactivity–mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Advances, 2019, 3, 2424-2435.	2.5	66
8	Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy. Acta Dermato-Venereologica, 2017, 97, 358-364.	0.6	57
9	Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Advances, 2020, 4, 1824-1832.	2.5	54
10	Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies. Scientific Reports, 2016, 6, 34382.	1.6	52
11	Case report. Medicine (United States), 2017, 96, e8303.	0.4	48
12	<i>BRAF</i> <sup>V600E</sup> Mutation in a Histiocytic Sarcoma Arising From Hairy Cell Leukemia. Journal of Clinical Oncology, 2014, 32, e117-e121.	0.8	47
13	Severe Aplastic Anemia Associated With Eosinophilic Fasciitis. Medicine (United States), 2013, 92, 69-81.	0.4	36
14	Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney International, 2014, 85, 182-190.	2.6	35
15	Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction. Nature Communications, 2021, 12, 6446.	5.8	35
16	Influence of bone marrow graft B lymphocyte subsets on outcome after HLAâ€identical sibling transplants. British Journal of Haematology, 2009, 145, 107-114.	1.2	29
17	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. Blood, 2020, 135, 1058-1061.	0.6	29
18	Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graftâ€versusâ€host disease. British Journal of Dermatology, 2017, 177, e206-e208.	1.4	25

DAVID MICHONNEAU

#	Article	IF	CITATIONS
19	Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 982-986.	1.3	25
20	CXCR3/CXCL10 Axis Shapes Tissue Distribution of Memory Phenotype CD8+ T Cells in Nonimmunized Mice. Journal of Immunology, 2018, 200, 139-146.	0.4	23
21	Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 392-400.	2.0	23
22	Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. Blood, 2022, 140, 1305-1321.	0.6	23
23	Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial. Blood, 2020, 135, 227-229.	0.6	20
24	Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study. Biology of Blood and Marrow Transplantation, 2018, 24, 2523-2531.	2.0	19
25	Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. Nephrology Dialysis Transplantation, 2013, 28, 471-478.	0.4	18
26	Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transplantation, 2021, 56, 1888-1899.	1.3	18
27	Overexpression of the antiapoptotic protein A1 promotes the survival of double positive thymocytes awaiting positive selection. Cell Death and Differentiation, 2006, 13, 1213-1221.	5.0	17
28	Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Dermatology, 2017, 153, 184.	2.0	17
29	Molecular characterization of subcutaneous panniculitis-like T-cell lymphoma reveals upregulation of immunosuppression- and autoimmunity-associated genes. Orphanet Journal of Rare Diseases, 2014, 9, 160.	1.2	16
30	Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. Blood Advances, 2020, 4, 3927-3942.	2.5	16
31	Treatment for pure red cell aplasia after major ABOâ€incompatible allogeneic stem cell transplantation: a multicentre study. British Journal of Haematology, 2021, 193, 814-826.	1.2	16
32	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer, 2019, 125, 90-98.	2.0	15
33	Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study. Blood, 2016, 128, 2285-2285.	0.6	15
34	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. Haematologica, 2021, 106, 2374-2383.	1.7	14
35	Indole derivatives, microbiome and graft versus host disease. Current Opinion in Immunology, 2021, 70, 40-47.	2.4	14
36	Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score. Bone Marrow Transplantation, 2020, 55, 1966-1974.	1.3	12

DAVID MICHONNEAU

#	Article	IF	CITATIONS
37	Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 1620-1626.	2.0	10
38	Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. Bone Marrow Transplantation, 2018, 53, 105-107.	1.3	9
39	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2490-2500.	2.0	9
40	A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. Bone Marrow Transplantation, 2020, 55, 86-92.	1.3	9
41	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. Biology of Blood and Marrow Transplantation, 2020, 26, 1160-1170.	2.0	9
42	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 38-49.	1.3	9
43	Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia, 2021, 35, 225-228.	3.3	9
44	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2020, 75, 2253-2257.	1.3	8
45	Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT. Blood Advances, 2017, 1, 1409-1413.	2.5	7
46	Chronic graftâ€versusâ€host disease and inhibition of interleukinâ€17: proof of concept in humans. British Journal of Dermatology, 2020, 182, 1038-1041.	1.4	7
47	Disseminated Scopulariopsis brevicaulis infection in an allogeneic stem cell recipient. Bone Marrow Transplantation, 2011, 46, 1276-1277.	1.3	6
48	RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea. Blood Advances, 2022, 6, 2805-2811.	2.5	6
49	Incidence, risk factors and outcome of BK virus hemorrhagic cystitis following allogenic hematopoietic cell transplantation: a retrospective cohort study. Bone Marrow Transplantation, 2022, 57, 1287-1294.	1.3	6
50	Recovery of full donor chimerism with ibrutinib therapy in relapsed <scp>CLL</scp> after allogeneic stem cell transplantation. British Journal of Haematology, 2017, 176, 997-999.	1.2	5
51	Alemtuzumab vs antiâ€ŧhymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. European Journal of Haematology, 2018, 101, 466-474.	1.1	5
52	Metabolomics Profiling after Allogeneic Hematopoietic Stem Cell Transplantation Unravels a Specific Signature in Human Acute GVHD. Blood, 2018, 132, 69-69.	0.6	5
53	Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. Science Translational Medicine, 2022, 14, eabg3083.	5.8	5
54	Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 2115-2120.	2.0	4

DAVID MICHONNEAU

#	Article	IF	CITATIONS
55	Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2021, 141, 193-197.e2.	0.3	4
56	Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial. Blood, 2016, 128, 65-65.	0.6	4
57	The virome in hematology—Stem cell transplantation and beyond. Seminars in Hematology, 2020, 57, 19-25.	1.8	4
58	Prospective external validation of biomarkers to predict acute graft-versus-host disease severity. Blood Advances, 2022, 6, 4763-4772.	2.5	4
59	Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2018, 132, 2139-2139.	0.6	3
60	GVHD Prophylaxis (Immunosuppression). , 2019, , 177-182.		3
61	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. Transplant Infectious Disease, 2022, 24, e13770.	0.7	3
62	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplantation, 2022, 57, 1365-1372.	1.3	3
63	InÂVivo Imaging of GVHD and GVL. , 2019, , 51-68.		2
64	Late-onset acute GVHD: clues for endothelial GVHD. Blood, 2016, 128, 2282-2283.	0.6	1
65	Chronic graft versus host disease presenting as lichen planus pigmentosus. Bone Marrow Transplantation, 2018, 53, 1048-1050.	1.3	1
66	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. Annals of Hematology, 2020, 99, 897-898.	0.8	1
67	Viromewide antibody responses after transplantation. Blood, 2019, 134, 493-495.	0.6	Ο
68	Clinical Characteristics, Biological Markers and Comorbidity Indexes As Predictors of Transplant-Related Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: Which One Should We Choose?. Blood, 2016, 128, 3478-3478.	0.6	0
69	Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome:the SFGM-TC Experience. Blood, 2018, 132, 3457-3457.	0.6	Ο
70	Germline TIM-3 Mutations Characterize Sub-Cutaneous Panniculitis T-Cell Lymphomas with Hemophagocytic Lymphohistiocytic Syndrome. Blood, 2018, 132, 1569-1569.	0.6	0